The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

PRASTERONE     (3S,8R,9S,10R,13S,14S)-3- hydroxy-10,13...

Synonyms: Astenile, Deandros, Diandron, Prestara, Vaginorm, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of PRASTERONE


Psychiatry related information on PRASTERONE


High impact information on PRASTERONE


Chemical compound and disease context of PRASTERONE


Biological context of PRASTERONE


Anatomical context of PRASTERONE


Associations of PRASTERONE with other chemical compounds


Gene context of PRASTERONE


Analytical, diagnostic and therapeutic context of PRASTERONE


  1. Dehydroepiandrosterone for adrenal insufficiency. Oelkers, W. N. Engl. J. Med. (1999) [Pubmed]
  2. Identification of virilizing adrenal tumors in hirsute women. Derksen, J., Nagesser, S.K., Meinders, A.E., Haak, H.R., van de Velde, C.J. N. Engl. J. Med. (1994) [Pubmed]
  3. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Labrie, F., Luu-The, V., Labrie, C., Bélanger, A., Simard, J., Lin, S.X., Pelletier, G. Endocr. Rev. (2003) [Pubmed]
  4. Androgens and coronary artery disease. Wu, F.C., von Eckardstein, A. Endocr. Rev. (2003) [Pubmed]
  5. Plasma dehydroepiandrosterone levels in HIV infection. Merril, C.R., Harrington, M.G., Sunderland, T. JAMA (1989) [Pubmed]
  6. DHEA therapy for women: effect on sexual function and wellbeing. Panjari, M., Davis, S.R. Hum. Reprod. Update (2007) [Pubmed]
  7. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. Gurnell, E.M., Hunt, P.J., Curran, S.E., Conway, C.L., Pullenayegum, E.M., Huppert, F.A., Compston, J.E., Herbert, J., Chatterjee, V.K. J. Clin. Endocrinol. Metab. (2008) [Pubmed]
  8. Neuroactive steroids and suicidality in posttraumatic stress disorder. Butterfield, M.I., Stechuchak, K.M., Connor, K.M., Davidson, J.R., Wang, C., MacKuen, C.L., Pearlstein, A.M., Marx, C.E. The American journal of psychiatry. (2005) [Pubmed]
  9. Changes in bone turnover markers and menstrual function after short-term oral DHEA in young women with anorexia nervosa. Gordon, C.M., Grace, E., Emans, S.J., Goodman, E., Crawford, M.H., Leboff, M.S. J. Bone Miner. Res. (1999) [Pubmed]
  10. Hyperinsulinaemia, dyslipidaemia and exaggerated adrenal androgen response to adrenocorticotropin in male smokers. Hautanen, A., Adlercreutz, H. Diabetologia (1993) [Pubmed]
  11. Double-blind treatment of major depression with dehydroepiandrosterone. Wolkowitz, O.M., Reus, V.I., Keebler, A., Nelson, N., Friedland, M., Brizendine, L., Roberts, E. The American journal of psychiatry. (1999) [Pubmed]
  12. Dehydroepiandrosterone and affective disorders. Hansen, C.R., Kroll, J., Mackenzie, T.B. The American journal of psychiatry. (1982) [Pubmed]
  13. Dehydroepiandrosterone improves psychological well-being in male and female hypopituitary patients on maintenance growth hormone replacement. Brooke, A.M., Kalingag, L.A., Miraki-Moud, F., Camacho-Hübner, C., Maher, K.T., Walker, D.M., Hinson, J.P., Monson, J.P. J. Clin. Endocrinol. Metab. (2006) [Pubmed]
  14. ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism. Siegel, S.F., Finegold, D.N., Lanes, R., Lee, P.A. N. Engl. J. Med. (1990) [Pubmed]
  15. A prospective study of dehydroepiandrosterone sulfate, mortality, and cardiovascular disease. Barrett-Connor, E., Khaw, K.T., Yen, S.S. N. Engl. J. Med. (1986) [Pubmed]
  16. Mechanism of feminization in primary liver cancer. Kew, M.C., Kirschner, M.A., Abrahams, G.E., Katz, M. N. Engl. J. Med. (1977) [Pubmed]
  17. Leydig-cell agenesis: a cause of male pseudohermaphroditism. Berthezène, F., Forest, M.G., Grimaud, J.A., Claustrat, B., Mornex, R. N. Engl. J. Med. (1976) [Pubmed]
  18. Clinical value of adrenal androgen measurement in the diagnosis of delayed puberty. Cohen, H.N., Wallace, A.M., Beastall, G.H., Fogelman, I., Thomson, J.A. Lancet (1981) [Pubmed]
  19. Physiological importance of dehydroepiandrosterone. Ebeling, P., Koivisto, V.A. Lancet (1994) [Pubmed]
  20. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Kimonides, V.G., Khatibi, N.H., Svendsen, C.N., Sofroniew, M.V., Herbert, J. Proc. Natl. Acad. Sci. U.S.A. (1998) [Pubmed]
  21. Is dehydroepiandrosterone an antiobesity agent? Berdanier, C.D., Parente, J.A., McIntosh, M.K. FASEB J. (1993) [Pubmed]
  22. Stimulation of cell proliferation and estrogenic response by adrenal C19-delta 5-steroids in the ZR-75-1 human breast cancer cell line. Poulin, R., Labrie, F. Cancer Res. (1986) [Pubmed]
  23. Premature adrenarche--normal variant or forerunner of adult disease? Ibáñez, L., Dimartino-Nardi, J., Potau, N., Saenger, P. Endocr. Rev. (2000) [Pubmed]
  24. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Labrie, F., Luu-The, V., Labrie, C., Simard, J. Frontiers in neuroendocrinology. (2001) [Pubmed]
  25. Inverse relation between low-density lipoprotein-cholesterol and dehydroisoandrosterone sulfate in human fetal plasma. Parker, C.R., Simpson, E.R., Bilheimer, D.W., Leveno, K., Carr, B.R., MacDonald, P.C. Science (1980) [Pubmed]
  26. Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. Daynes, R.A., Araneo, B.A., Dowell, T.A., Huang, K., Dudley, D. J. Exp. Med. (1990) [Pubmed]
  27. Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. Couillard, S., Labrie, C., Bélanger, A., Candas, B., Pouliot, F., Labrie, F. J. Natl. Cancer Inst. (1998) [Pubmed]
  28. Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury. Gordon, G.B., Bush, D.E., Weisman, H.F. J. Clin. Invest. (1988) [Pubmed]
  29. Adrenal steroids and the development of osteoporosis in oophorectomised women. Manolagas, S.C., Anderson, D.C., Lindsay, R. Lancet (1979) [Pubmed]
  30. Astrocytes and neurosteroids: metabolism of pregnenolone and dehydroepiandrosterone. Regulation by cell density. Akwa, Y., Sananès, N., Gouézou, M., Robel, P., Baulieu, E.E., Le Goascogne, C. J. Cell Biol. (1993) [Pubmed]
  31. Glucocorticoid receptor pathways are involved in the inhibition of astrocyte proliferation. Crossin, K.L., Tai, M.H., Krushel, L.A., Mauro, V.P., Edelman, G.M. Proc. Natl. Acad. Sci. U.S.A. (1997) [Pubmed]
  32. Age-dependent regulation of chromaffin cell proliferation by growth factors, dehydroepiandrosterone (DHEA), and DHEA sulfate. Sicard, F., Ehrhart-Bornstein, M., Corbeil, D., Sperber, S., Krug, A.W., Ziegler, C.G., Rettori, V., McCann, S.M., Bornstein, S.R. Proc. Natl. Acad. Sci. U.S.A. (2007) [Pubmed]
  33. Impact of growth hormone and dehydroepiandrosterone on protein metabolism in glucocorticoid-treated patients. Burt, M.G., Johannsson, G., Umpleby, A.M., Chisholm, D.J., Ho, K.K. J. Clin. Endocrinol. Metab. (2008) [Pubmed]
  34. Lack of dehydroepiandrosterone effect on a combined endurance and resistance exercise program in postmenopausal women. Igwebuike, A., Irving, B.A., Bigelow, M.L., Short, K.R., McConnell, J.P., Nair, K.S. J. Clin. Endocrinol. Metab. (2008) [Pubmed]
  35. Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. Naylor, J.C., Hulette, C.M., Steffens, D.C., Shampine, L.J., Ervin, J.F., Payne, V.M., Massing, M.W., Kilts, J.D., Strauss, J.L., Calhoun, P.S., Calnaido, R.P., Blazer, D.G., Lieberman, J.A., Madison, R.D., Marx, C.E. J. Clin. Endocrinol. Metab. (2008) [Pubmed]
  36. Dehydroepiandrosterone can inhibit the proliferation of myeloma cells and the interleukin-6 production of bone marrow mononuclear cells from patients with myeloma. Liu, S., Ishikawa, H., Li, F.J., Ma, Z., Otsuyama, K., Asaoku, H., Abroun, S., Zheng, X., Tsuyama, N., Obata, M., Kawano, M.M. Cancer Res. (2005) [Pubmed]
  37. Crystal structure of human cholesterol sulfotransferase (SULT2B1b) in the presence of pregnenolone and 3'-phosphoadenosine 5'-phosphate. Rationale for specificity differences between prototypical SULT2A1 and the SULT2BG1 isoforms. Lee, K.A., Fuda, H., Lee, Y.C., Negishi, M., Strott, C.A., Pedersen, L.C. J. Biol. Chem. (2003) [Pubmed]
  38. The steroid hormone dehydroepiandrosterone inhibits CYP1A1 expression in vitro by a post-transcriptional mechanism. Ciolino, H.P., Yeh, G.C. J. Biol. Chem. (1999) [Pubmed]
  39. Specific binding of dehydroepiandrosterone to the N terminus of the microtubule-associated protein MAP2. Laurine, E., Lafitte, D., Grégoire, C., Sérée, E., Loret, E., Douillard, S., Michel, B., Briand, C., Verdier, J.M. J. Biol. Chem. (2003) [Pubmed]
  40. The orphan nuclear receptor NGFIB regulates transcription of 3beta-hydroxysteroid dehydrogenase. implications for the control of adrenal functional zonation. Bassett, M.H., Suzuki, T., Sasano, H., De Vries, C.J., Jimenez, P.T., Carr, B.R., Rainey, W.E. J. Biol. Chem. (2004) [Pubmed]
  41. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjögren's syndrome. Laine, M., Porola, P., Udby, L., Kjeldsen, L., Cowland, J.B., Borregaard, N., Hietanen, J., Ståhle, M., Pihakari, A., Konttinen, Y.T. Arthritis Rheum. (2007) [Pubmed]
  42. Dehydroepiandrosterone stimulates phosphorylation of FoxO1 in vascular endothelial cells via phosphatidylinositol 3-kinase- and protein kinase A-dependent signaling pathways to regulate ET-1 synthesis and secretion. Chen, H., Lin, A.S., Li, Y., Reiter, C.E., Ver, M.R., Quon, M.J. J. Biol. Chem. (2008) [Pubmed]
  43. Dehydroepiandrosterone replacement in women with adrenal insufficiency. Arlt, W., Callies, F., van Vlijmen, J.C., Koehler, I., Reincke, M., Bidlingmaier, M., Huebler, D., Oettel, M., Ernst, M., Schulte, H.M., Allolio, B. N. Engl. J. Med. (1999) [Pubmed]
  44. Sex-specific action of insulin to acutely increase the metabolic clearance rate of dehydroepiandrosterone in humans. Nestler, J.E., Kahwash, Z. J. Clin. Invest. (1994) [Pubmed]
  45. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Strous, R.D., Maayan, R., Lapidus, R., Stryjer, R., Lustig, M., Kotler, M., Weizman, A. Arch. Gen. Psychiatry (2003) [Pubmed]
WikiGenes - Universities